Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 8/2018

01-08-2018 | Neuro-oncology (S Nagpal, Section Editor)

The Utility of Liquid Biopsy in Central Nervous System Malignancies

Authors: Kathryn S. Nevel, Jessica A. Wilcox, Lindsay J. Robell, Yoshie Umemura

Published in: Current Oncology Reports | Issue 8/2018

Login to get access

Abstract

Purpose of Review

Liquid biopsy is a sampling of tumor cells or tumor nucleotides from biofluids. This review explores the roles of liquid biopsy for evaluation and management of patients with primary and metastatic CNS malignancies.

Recent Findings

Circulating tumor cell (CTC) detection has emerged as a relatively sensitive and specific tool for diagnosing leptomeningeal metastases. Circulating tumor DNA (ctDNA) detection can effectively demonstrate genetic markup of CNS tumors in the cerebrospinal fluid, though its role in managing CNS malignancies is less well-defined. The value of micro RNA (miRNA) detection in CNS malignancies is unclear at this time.

Summary

Current standard clinical tools for the diagnosis and monitoring of CNS malignancies have limitations, and liquid biopsy may help address clinical practice and knowledge gaps. Liquid biopsy offers exciting potential for the diagnosis, prognosis, and treatment of CNS malignancies, but each modality needs to be studied in large prospective trials to better define their use.
Literature
1.
Lonjaret L et al.. Postoperative complications after craniotomy for brain tumor surgery. Anaesth Crit Care Pain Med, 2016.
2.
Lassen B, Helseth E, Rønning P, Scheie D, Johannesen TB, Mæhlen J, et al. Surgical mortality at 30 days and complications leading to recraniotomy in 2630 consecutive craniotomies for intracranial tumors. Neurosurgery. 2011;68(5):1259–68. discussion 1268–9CrossRefPubMed
3.
Twijnstra A, Nooyen WJ, van Zanten AP, Hart AAM, de Visser BWO. Cerebrospinal fluid carcinoembryonic antigen in patients with metastatic and nonmetastatic neurological diseases. Arch Neurol. 1986;43(3):269–72.CrossRefPubMed
4.
Twijnstra A, van Zanten AP, Nooyen WJ, Ongerboer de Visser BW. Sensitivity and specificity of single and combined tumour markers in the diagnosis of leptomeningeal metastasis from breast cancer. J Neurol Neurosurg Psychiatry. 1986;49(11):1246–50.CrossRefPubMedPubMedCentral
5.
Zhang Z, Tian C, Shi Q, Hao J, Zhao N, Liu Z. Diagnostic value of CYFRA 21-1 in the cerebrospinal fluid for leptomeningeal metastasis. Dis Markers. 2017;2017:2467870.PubMedPubMedCentral
6.
Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008;9(5):453–61.CrossRefPubMed
7.
Cohen JV, Alomari AK, Vortmeyer AO, Jilaveanu LB, Goldberg SB, Mahajan A, et al. Melanoma brain metastasis pseudoprogression after pembrolizumab treatment. Cancer Immunol Res. 2016;4(3):179–82.CrossRefPubMed
8.
Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57.CrossRefPubMed
9.
Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–42.CrossRefPubMed
10.
11.
Krebs MG, Hou JM, Ward TH, Blackhall FH, Dive C. Circulating tumour cells: their utility in cancer management and predicting outcomes. Ther Adv Med Oncol. 2010;2:351–65.CrossRefPubMedPubMedCentral
12.
Hong Y, Zhang Q. Phenotype of circulating tumor cell: face-off between epithelial and mesenchymal masks. Tumor Biol. 2016;37:5663–74.CrossRef
13.
Ashworth TR. A case of cancer in which cells similar to the tumours were seen in the blood after death. Med J Aust. 1869;14:146–7.
14.
Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, et al. Isolation and characterization of circulating tumor cells from localized and metastatic prostate cancer patients. Sci Transl Med. 2010;2(25):25ra23.CrossRefPubMedPubMedCentral
15.
Racila E, Euhus D, Weiss AJ, Rao C, McConnell J, Terstappen LWMM, et al. Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci U S A. 1998;95(8):4589–94.CrossRefPubMedPubMedCentral
16.
Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781–91.CrossRefPubMed
17.
Negin BP, Cohen SJ. Circulating tumor cells in colorectal cancer: past, present, and future challenges. Curr Treat Options in Oncol. 2010;11(1–2):1–13.CrossRef
18.
Galletti G, Portella L, Tagawa ST, Kirby BJ, Giannakakou P, Nanus DM. Circulating tumor cells in prostate Cancer diagnosis and monitoring: an appraisal of clinical potential. Mol Diagn Ther. 2014;18(4):389–402.CrossRefPubMedPubMedCentral
19.
Kojima T, Hashimoto Y, Watanabe Y, Kagawa S, Uno F, Kuroda S, et al. A simple biological imaging system for detecting viable human circulating tumor cells. J Clin Invest. 2009;119(10):3172–81.CrossRefPubMedPubMedCentral
20.
Nagrath S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2009, 450:1235–9.
21.
Ning M, et al. Diagnostic value of circulating tumor cells in cerebrospinal fluid. Open Med (Wards). 2016;11(1):21–4.
22.
23.
Balasubramanian P, Kinders RJ, Kummar S, Gupta V, Hasegawa D, Menachery A, et al. Antibody-independent capture of circulating tumor cells of non-epithelial origin with the ApoStream® system. PLoS One. 2017;12(4):e0175414.CrossRefPubMedPubMedCentral
24.
Yan WT, Cui X, Chen Q, Li YF, Cui YH, Wang Y, et al. Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis. Sci Rep. 2017;7:43464.CrossRefPubMedPubMedCentral
25.
Cohen SJ, Punt CJA, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(19):3212–21.CrossRef
26.
de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14(19):6302–9.CrossRefPubMed
27.
Fehm T, Becker S, Duerr-Stoerzer S, Sotlar K, Mueller V, Wallwiener D, et al. Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res. 2007;9(55):R74.CrossRefPubMedPubMedCentral
28.
Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008;359:366–77.CrossRefPubMedPubMedCentral
29.
Bidard F-C, Fehm T, Ignatiadis M, Smerage JB, Alix-Panabières C, Janni W, et al. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev. 2013;32(1):179–88.CrossRefPubMed
30.
Patel AS, Allen JE, Dicker DT, Peters KL, Sheehan JM, Glantz MJ, et al. Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases. Oncotarget. 2011;2(10):752–60.CrossRefPubMedPubMedCentral
31.
Nayak L, Fleisher M, Gonzalez-Espinoza R, Lin O, Panageas K, Reiner A, et al. Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors. Neurology. 2013;80(17):1598–605. discussion 1603CrossRefPubMedPubMedCentral
32.
Lee JS, Melisko ME, Magbanua MJM, Kablanian AT, Scott JH, Rugo HS, et al. Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer. Breast Cancer Res Treat. 2015;154(2):339–49.CrossRefPubMed
33.
• Lin X, et al. Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors. Neuro-Oncology. 2017;19(9):1248–54. This paper revealed the high sensitivity and specificity of CSF circulating tumor cell detection to diagnose leptomeningeal metastasis from solid tumor malignancies of epithelial cell origin. CrossRefPubMedPubMedCentral
34.
Malani R et al.. Cerebrospinal fluid circulating tumor cells (CSF CTC) for real-time patient monitoring and response to treatment. J Clin Oncol, 2017. 35: p. suppl; abstr 11549.
35.
Tug S, Helmig S, Menke J, Zahn D, Kubiak T, Schwarting A, et al. Correlation between cell free DNA levels and medical evaluation of disease progression in systemic lupus erythematosus patients. Cell Immunol. 2014;292(1–2):32–9.CrossRefPubMed
36.
37.
Szpechcinski A, Rudzinski P, Kupis W, Langfort R, Orlowski T, Chorostowska-Wynimko J. Plasma cell-free DNA levels and integrity in patients with chest radiological findings: NSCLC versus benign lung nodules. Cancer Lett. 2016;374(2):202–7.CrossRefPubMed
38.
Ai B, Liu H, Huang Y, Peng P. Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer. Oncotarget. 2016;7(28):44583–95.CrossRefPubMedPubMedCentral
39.
Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37(3):646–50.PubMed
40.
Sorenson GD, et al. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomark Prev. 1994;3(1):67–71.
41.
Schwarzenbach H, Pantel K, Kemper B, Beeger C, Otterbach F, Kimmig R, et al. Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer. Breast Cancer Res. 2009;11(5):R71.CrossRefPubMedPubMedCentral
42.
van der Vaart M, Pretorius PJ. Circulating DNA. Its origin and fluctuation. Ann N Y Acad Sci. 2008;1137:18–26.CrossRefPubMed
43.
Crowley E, di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013;10(8):472–84.CrossRefPubMed
44.
Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985–90.CrossRefPubMed
45.
• Pentsova EI, et al. Evaluating cancer of the central nervous system through next-generation sequencing of cerebrospinal fluid. J Clin Oncol. 2016;34(20):2404–15. This study demonstrated that ctDNA in the CSF can be analyzed to assess for clinically relevant genomic alterations in patients with CNS cancers. ctDNA in the CSF can reveal clinically important mutations that help guide treatment decisions, and show early mechanisms of drug resistance. CrossRefPubMedPubMedCentral
46.
• Wang Y, et al. Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. Proc Natl Acad Sci U S A. 2015;112(31):9704–9. This study showed that CSF ctDNA can be used in lieu of a tissue biopsy in surgically high-risk patients. It also importantly showed that CSF ctDNA is of highest yield in patients with tumors that abut the ventricle. CrossRefPubMedPubMedCentral
47.
Dressman D, Yan H, Traverso G, Kinzler KW, Vogelstein B. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A. 2003;100(15):8817–22.CrossRefPubMedPubMedCentral
48.
Diehl F, Li M, He Y, Kinzler KW, Vogelstein B, Dressman D. BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nat Methods. 2006;3(7):551–9.CrossRefPubMed
49.
Chen WW, Balaj L, Liau LM, Samuels ML, Kotsopoulos SK, Maguire CA, et al. BEAMing and droplet digital PCR analysis of mutant IDH1 mRNA in glioma patient serum and cerebrospinal fluid extracellular vesicles. Mol Ther Nucleic Acids. 2013;2:e109.CrossRefPubMedPubMedCentral
50.
Newman AM, Bratman SV, To J, Wynne JF, Eclov NCW, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20(5):548–54.CrossRefPubMedPubMedCentral
51.
52.
Sie D, Snijders PJF, Meijer GA, Doeleman MW, van Moorsel MIH, van Essen HF, et al. Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology. Cell Oncol (Dordr). 2014;37(5):353–61.CrossRef
53.
Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24.CrossRefPubMedPubMedCentral
54.
Olsson E, Winter C, George A, Chen Y, Howlin J, Tang MHE, et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol Med. 2015;7(8):1034–47.CrossRefPubMedPubMedCentral
55.
Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015;7(302):302ra133.CrossRefPubMed
56.
Tie J, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8(346):346ra92.CrossRefPubMedPubMedCentral
57.
Nygaard AD, Garm Spindler KL, Pallisgaard N, Andersen RF, Jakobsen A. The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer. Lung Cancer. 2013;79(3):312–7.CrossRefPubMed
58.
Parkinson CA, Gale D, Piskorz AM, Biggs H, Hodgkin C, Addley H, et al. Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study. PLoS Med. 2016;13(12):e1002198.CrossRefPubMedPubMedCentral
59.
Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun. 2016;7:11815.CrossRefPubMedPubMedCentral
60.
Salkeni MA, Zarzour A, Ansay TY, McPherson CM, Warnick RE, Rixe O, et al. Detection of EGFRvIII mutant DNA in the peripheral blood of brain tumor patients. J Neuro-Oncol. 2013;115(1):27–35.CrossRef
61.
Balana C, et al. O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clin Cancer Res. 2003;9(4):1461–8.PubMed
62.
Lavon I, Refael M, Zelikovitch B, Shalom E, Siegal T. Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades. Neuro-Oncology. 2010;12(2):173–80.CrossRefPubMedPubMedCentral
63.
Shi W, Lv C, Qi J, Zhao W, Wu X, Jing R, et al. Prognostic value of free DNA quantification in serum and cerebrospinal fluid in glioma patients. J Mol Neurosci. 2012;46(3):470–5.CrossRefPubMed
64.
• De Mattos-Arruda L, et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun. 2015;6:8839. This study showed that CSF ctDNA is more abundant than serum ctDNA in patients with CNS malginancies, and can be used as an adjunct tool to diagnose leptomeningeal metastasis. CrossRefPubMedPubMedCentral
65.
66.
Liu BL, Cheng JX, Zhang W, Zhang X, Wang R, Lin H, et al. Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas. Neuro-Oncology. 2010;12(6):540–8.CrossRefPubMedPubMedCentral
67.
Swinkels DW, de Kok JB, Hanselaar A, Lamers K, Boerman RH. Early detection of leptomeningeal metastasis by PCR examination of tumor-derived K-ras DNA in cerebrospinal fluid. Clin Chem. 2000;46(1):132–3.PubMed
68.
Shingyoji M, Kageyama H, Sakaida T, Nakajima T, Matsui Y, Itakura M, et al. Detection of epithelial growth factor receptor mutations in cerebrospinal fluid from patients with lung adenocarcinoma suspected of neoplastic meningitis. J Thorac Oncol. 2011;6(7):1215–20.CrossRefPubMed
69.
Yang H, Cai L, Zhang Y, Tan H, Deng Q, Zhao M, et al. Sensitive detection of EGFR mutations in cerebrospinal fluid from lung adenocarcinoma patients with brain metastases. J Mol Diagn. 2014;16(5):558–63.CrossRefPubMed
70.
Sasaki S, Yoshioka Y, Ko R, Katsura Y, Namba Y, Shukuya T, et al. Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure. Respir Investig. 2016;54(1):14–9.CrossRefPubMed
71.
Kimoto T, Inoue M, Tokimasa S, Yagyu S, Iehara T, Hosoi H, et al. Detection of MYCN DNA in the cerebrospinal fluid for diagnosing isolated central nervous system relapse in neuroblastoma. Pediatr Blood Cancer. 2011;56(5):865–7.CrossRefPubMed
72.
Momtaz P, Pentsova E, Abdel-Wahab O, Diamond E, Hyman D, Merghoub T, et al. Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies. Oncotarget. 2016;7(51):85430–6.CrossRefPubMedPubMedCentral
73.
Li Y, Pan W, Connolly ID, Reddy S, Nagpal S, Quake S, et al. Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases. J Neuro-Oncol. 2016;128(1):93–100.CrossRef
74.
75.
Areeb Z, Stylli SS, Koldej R, Ritchie DS, Siegal T, Morokoff AP, et al. MicroRNA as potential biomarkers in glioblastoma. J Neuro-Oncol. 2015;125(2):237–48.CrossRef
76.
Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 2005;65(14):6029–33.CrossRefPubMed
77.
78.
Yan W, Li R, Liu Y, Yang P, Wang Z, Zhang C, et al. MicroRNA expression patterns in the malignant progression of gliomas and a 5-microRNA signature for prognosis. Oncotarget. 2014;5(24):12908–15.CrossRefPubMedPubMedCentral
79.
Qiu S, Lin S, Hu D, Feng Y, Tan Y, Peng Y. Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients. J Transl Med. 2013;11:10.CrossRefPubMedPubMedCentral
80.
Zhang W, et al. Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme. Cancer Biol Ther. 2015;119(4):814–24.
81.
Berthois Y, et al. Differential expression of miR200a-3p and miR21 in grade II-III and grade IV gliomas: evidence that miR200a-3p is regulated by O(6)-methylguanine methyltrans-ferase and promotes temozolomide responsiveness. Cancer Biol Ther. 2014;15(7):938–50.CrossRefPubMedPubMedCentral
82.
Hayes J, Thygesen H, Tumilson C, Droop A, Boissinot M, Hughes TA, et al. Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signture. Mol Oncol. 2015;9(3):704–14.CrossRefPubMed
83.
Niyazi M, et al. A 4-miRNA signature predicts the therapeutic outcome of glioblastoma. Oncotarget. 2016;7(29):45764–75.PubMedPubMedCentral
84.
Barbano R, Palumbo O, Pasculli B, Galasso M, Volinia S, D'Angelo V, et al. A miRNA signature for defining aggressive phenotype and prognosis in gliomas. PLoS One. 2014;9(10):e108950.CrossRefPubMedPubMedCentral
85.
Guan Y, Mizoguchi M, Yoshimoto K, Hata N, Shono T, Suzuki SO, et al. MiRNA-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance. Clin Cancer Res. 2010;16(16):4289–97.CrossRefPubMed
86.
Akers JC, Ramakrishnan V, Kim R, Phillips S, Kaimal V, Mao Y, et al. miRNA contents of cerebrospinal fluid extracellular vesicles in glioblastoma patients. J Neuro-Oncol. 2015;123:205–16.CrossRef
87.
Yue X, Lan FM, Hu M, Pan Q, Wang Q, Wang JH. Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma. J Neurosurg. 2016;124:122–8.CrossRefPubMed
88.
Xiao Y, Zhang L, Song Z, Guo C, Zhu J, Li Z, et al. Potential diagnostic and prognostic value of plasma circulating MicroRNA-182 in human Glioma. Med Sci Monit. 2016;22:855–62.CrossRefPubMedPubMedCentral
89.
Yang C, Wang C, Chen X, Chen S, Zhang Y, Zhi F, et al. Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas. Int J Cancer. 2013;132:116–27.CrossRefPubMed
90.
Zhi F, Shao N, Wang R, Deng D, Xue L, Wang Q, et al. Identification of 9 serum microRNAs as potential noninvasive biomarkers of human astrocytoma. Neuro-Oncology. 2015;17(3):383–91.CrossRefPubMed
91.
Zhao H, Shen J, Hodges TR, Song R, Fuller GN, Heimberger AB. Serum microRNA profiling in patients with glioblastoma: a survival analysis. Mol Cancer. 2017;16(1):59.CrossRefPubMedPubMedCentral
92.
Drusco A, Bottoni A, Laganà A, Acunzo M, Fassan M, Cascione L, et al. A differentially expressed set of microRNAs in cerebro-spinal fluid can diagnose CNS malignancies. Oncotarget. 2015;6:20829–39.CrossRefPubMedPubMedCentral
93.
Teplyuk NM, Mollenhauer B, Gabriely G, Giese A, Kim E, Smolsky M, et al. MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro-Oncology. 2012;14(6):689–700.CrossRefPubMedPubMedCentral
94.
Baraniskin A, Kuhnhenn J, Schlegel U, Maghnouj A, Zollner H, Schmiegel W, et al. Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma. Neuro-Oncology. 2012;14(1):29–33.CrossRefPubMed
95.
Baraniskin A, Kuhnhenn J, Schlegel U, Chan A, Deckert M, Gold R, et al. Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood. 2011;117(11):3140–6.CrossRefPubMed
96.
• Shi R, Wang PY, Li XY, Chen JX, Li Y, Zhang XZ, et al. Exosomal levels of miRNA-21 from cerebrospinal fluids associated with poor prognosis and tumor recurrence of glioma patients. Oncotarget. 2015;6(29):26971–81. This study demonstrated that miRNA-21 is present in significantly higher levels in the CSF of glioblastoma patients compared to brain trauma controls. These levels were associated with tumor grade and negatively correlated with median overall survival. CrossRefPubMedPubMedCentral
97.
Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov. 2015;5(11):1164–77.CrossRefPubMedPubMedCentral
98.
Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014;344(6190):1396–401.CrossRefPubMedPubMedCentral
99.
Parker NR, Hudson AL, Khong P, Parkinson JF, Dwight T, Ikin RJ, et al. Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma. Sci Rep. 2016;6:22477.CrossRefPubMedPubMedCentral
Metadata
Title
The Utility of Liquid Biopsy in Central Nervous System Malignancies
Authors
Kathryn S. Nevel
Jessica A. Wilcox
Lindsay J. Robell
Yoshie Umemura
Publication date
01-08-2018
Publisher
Springer US
Published in
Current Oncology Reports / Issue 8/2018
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-018-0706-x

Other articles of this Issue 8/2018

Current Oncology Reports 8/2018 Go to the issue

Integrative Care (C Lammersfeld, Section Editor)

Flaxseed Bioactive Compounds and Colorectal Cancer Prevention

Cardio-oncology (EH Yang, Section Editor)

Tyrosine Kinase Inhibitor-Induced Hypertension

Integrative Care (C Lammersfeld, Section Editor)

Toxicity of Cancer Therapies in Older Patients

Gastrointestinal Cancers (J Meyer, Section Editor)

Peritoneal Metastases from Gastrointestinal Cancer

Breast Cancer (B Overmoyer, Section Editor)

Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?

Breast Cancer (B Overmoyer, Section Editor)

Cardiac Toxicity from Breast Cancer Treatment: Can We Avoid This?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits